Stay updated on ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.

Latest updates to the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference1%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check71 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check86 days agoChange DetectedThe page has removed detailed information about a phase 2 study of abraxane with pembrolizumab for advanced urothelial carcinoma, including inclusion and exclusion criteria, while adding a reference to Urothelial Carcinoma and a new revision number.SummaryDifference34%
Stay in the know with updates to ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.